DARIC 33
Alternative Names: CD33 targeted regulatable CAR T; DARIC33; SC-DARIC33Latest Information Update: 29 May 2024
At a glance
- Originator bluebird bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 01 Apr 2024 Regeneron Pharmaceuticals acquires anti-cancer immune cell therapies from 2seventy bio
- 04 Mar 2024 2seventy bio re-initiates the phase I PLAT-08 trial in Acute myeloid leukemia (In adolescents, In children, In adults, In infants, In neonates, Second-line therapy or greater) in USA (Parenteral, Infusion) before March 2024(NCT05105152)
- 31 Dec 2023 US FDA lifts a clinical hold on the phase I PLAT-08 trial in December 2023